secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2022-03-31T23:59:59+00:00
Accession:  0001193125-22-091856
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech reports FY2021 net loss of $67.9M; cash of $211.5M supports operations into mid-2024
--------------------------------------------------------------------------------

- Net loss $67.9M in FY2021 vs $12.0M in FY2020; R&D expenses rose to $30.2M from $8.5M.
- Cash and cash equivalents of $211.5M at Dec 31, 2021; expected runway through multiple data readouts into mid-2024.
- Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 + KEYTRUDA in advanced melanoma began patient recruitment.
- Updated Phase 1/2 data (MM1636) in metastatic melanoma to be presented at AACR 2022.
- Management notes longer-than-expected lead times in clinical site activation and patient enrollment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522091856/0001193125-22-091856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522091856/d342643d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-091856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer